S. 1584 · 116th Congress
Opioid Crisis Accountability Act of 2019
Key: what the circles and colors mean
Each circle is a bill. The ring fills as it moves through Congress:
Under the number: the Yea · Nay count of its final (or latest) recorded vote. On a member's page, the small badge is how that member voted: Y Yea / Aye, N Nay / No, P Present, – Not voting.
Gold and violet are only for Yea and Nay; they never mean a party. A member's party is the letter on their photo.
Never voted on. It didn't reach a floor vote before the 116th Congress ended, so it expired. A bill has to be introduced again to be considered in a new Congress.
I
SandersSponsor3 cosponsors · 3 D
3 signed on when it was introduced; the rest joined later. Cosponsors who withdrew aren't shown.
This bill establishes a series of restrictions and requirements relating to opioid marketing and distribution practices.
What it does: CRS summary · Introduced in Senate · May 21, 2019
Opioid Crisis Accountability Act of 2019
This bill establishes a series of restrictions and requirements relating to opioid marketing and distribution practices.
Specifically, the bill prohibits (1) knowingly making false advertising or marketing claims regarding the addictive nature of opioids; (2) knowingly supplying communities with quantities of opioids that are not medically reasonable; or (3) failing to report distribution orders, or patterns of orders, while knowing that the orders are not being dispensed in a medically reasonable manner. Employees of opioid manufacturers and distributors are subject to civil penalties and imprisonment for violations; corporations and executives are subject to civil penalties. Manufacturers shall also lose their period of market exclusivity.
Additionally, the Department of Health and Human Services must assess a fee against each corporation that, between January 1, 1993, and the date of enactment of this bill, manufactured or distributed opioids, if such opioids were covered under a federal health program at least once during this period. Manufacturers that fail to pay the fee shall lose associated drug approval until the fee is paid in full.
The bill authorizes collected civil penalties and fees to be used for activities that address opioid misuse and abuse, including family and educational programs.
Written by the nonpartisan Congressional Research Service. All summary versions on Congress.gov
About this bill and sources
Official title: Opioid Crisis Accountability Act of 2019
Latest action (May 21, 2019): Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Policy area: Health · Origin: Senate · Introduced: May 21, 2019
Official page on Congress.gov · Bill text (GovInfo) · Status record (XML)
No recorded floor vote found.